Is it time for treat to target strategy in osteoporosis?

被引：11

作者：

Chapurlat, Roland ^{[1
,2
]}

机构：

[1] Univ Lyon, INSERM, UMR 1033, F-69437 Lyon, France

[2] Hop Edouard Herriot, Serv Rhumatol & Pathol Osseuse, 5 Pl Arsonval, F-69437 Lyon, France

来源：

JOINT BONE SPINE | 2016年 / 83卷 / 04期

关键词：

Osteoporosis; Fracture; Bisphosphonates; Denosumab; Bone mineral density; BONE-MINERAL DENSITY; FRACTURE RISK; VERTEBRAL FRACTURE; WOMEN; ALENDRONATE; EFFICACY; REDUCTION; THERAPY;

D O I：

10.1016/j.jbspin.2015.12.002

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：381 / 383

页数：3

共 20 条

[1]

[Anonymous], 1995, BMJ, V310, P83

[2]

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures [J].

Austin, Matthew ;

Yang, Yu-Ching ;

Vittinghoff, Eric ;

Adami, Silvano ;

Boonen, Steven ;

Bauer, Douglas C. ;

Bianchi, Gerolamo ;

Bolognese, Michael A. ;

Christiansen, Claus ;

Eastell, Richard ;

Grauer, Andreas ;

Hawkins, Federico ;

Kendler, David L. ;

Oliveri, Beatriz ;

McClung, Michael R. ;

Reid, Ian R. ;

Siris, Ethel S. ;

Zanchetta, Jose ;

Zerbini, Cristiano A. F. ;

Libanati, Cesar ;

Cummings, Steven R. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :687-693

[3]

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[4]

Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study [J].

Bauer, Douglas C. ;

Schwartz, Ann ;

Palermo, Lisa ;

Cauley, Jane ;

Hochberg, Marc ;

Santora, Art ;

Cummings, Steven R. ;

Black, Dennis M. .

JAMA INTERNAL MEDICINE, 2014, 174 (07) :1126-1134

[5]

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].

Black, Dennis M. ;

Reid, Ian R. ;

Boonen, Steven ;

Bucci-Rechtweg, Christina ;

Cauley, Jane A. ;

Cosman, Felicia ;

Cummings, Steven R. ;

Hue, Trisha F. ;

Lippuner, Kurt ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Martinez, Ruvie Lou Maria ;

Tan, Monique ;

Ruzycky, Mary Ellen ;

Su, Guoqin ;

Eastell, Richard .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254

[6]

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial [J].

Chapurlat, RD ;

Palermo, L ;

Ramsay, P ;

Cummings, SR .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (07) :842-848

[7]

Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database [J].

Confavreux, Cyrille B. ;

Canoui-Poitrine, Florence ;

Schott, Anne-Marie ;

Ambrosi, Veronique ;

Tainturier, Valerie ;

Chapurlat, Roland D. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (04) :735-741

[8]

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate [J].

Eastell, R ;

Barton, I ;

Hannon, RA ;

Chines, A ;

Garnero, P ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1051-1056

[9]

Treat-to-target trials: uses, interpretation and review of concepts [J].

Garber, A. J. .

DIABETES OBESITY & METABOLISM, 2014, 16 (03) :193-205

[10]

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT) [J].

Jacques, Richard M. ;

Boonen, Steven ;

Cosman, Felicia ;

Reid, Ian R. ;

Bauer, Douglas C. ;

Black, Dennis M. ;

Eastell, Richard .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (08) :1627-1634

← 1 2 →